COVID-19 Update: Learn how New York Proton Center is taking all the necessary precautions to keep you safe.

A standard of care, grounded in research

There is a large and compelling body of clinical evidence showing that, for many cancers, proton therapy is overall safer and more effective than conventional radiation, particularly for complex and difficult-to-treat tumors.


And yet, many insurance companies still deny coverage. This is a key reason the New York Proton Center invests so heavily in proton therapy research.


The New York Proton Center has developed a one-of-a-kind research program that aims to further the evidence supporting proton therapy and, in doing so, to make this potentially lifesaving treatment more widely available to patients.


Life Advances®

With its large and productive research division, the New York Proton Center is furthering the body of clinical evidence advancing proton therapy treatment. It is a vibrant hub of activity—laboratory work, clinical trials, translational science, physics research—aimed at producing high quality data, driving best-practice guidelines, and reaffirming proton therapy as a well-established, standard-of-care treatment.

Clinical Trials

As one of its primary objectives, our dynamic research program is working to identify which patients stand to benefit the most from proton therapy. Many of our radiation oncologists are leading large national clinical trials that are available to our patients. Ninety-seven percent (97%) of our patients are enrolled in one of these studies or in one of the many other clinical trials available at our Center.


Patients interested in participating in any of these trials should speak to their radiation oncologist about eligibility.

The following trials are currently enrolling patients:

Breast Cancer

PCG BRE 007-12  Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer: NCT01766297


RadComp/RTOG 3510 Pragmatic Phase III Randomized Trial of Proton Versus Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: NCT02603341


PCG BRE 009-23 Phase III Randomized Trial of Conventionally Fractionated vs. Hypofractionated COMprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning PROton Therapy (COMPRO): NCT05856773

Gastrointestinal Cancers

NRG GI003 A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma: NCT03186898


NRG GI006 Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer: NCT03801876

Head and Neck Cancers

MSK 16-1416 A Phase II Randomized Study of Proton Versus Photon Beam Radiotherapy in the Treatment of Unilateral Head and Neck Cancer: NCT02923570


ECOG-ACRIN EA3191 A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High-Risk Features​: NCT04671667

Pediatric Cancers

Proton and Photon Consortium Registry (PPCR) A Multi Center Registry of Pediatric Patients Treated with Radiation Therapy: NCT01696721


MSK 14-186 Local Control with Reduced-dose Radiotherapy for High-Risk Neuroblastoma: NCT02245997


COG ACNS1723 A Phase II Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (IND# 145355): NCT03919071


COG ARST2031 A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma: NCT04994132


COG ACNS2021 A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor: NCT04684368


PAC PED23-022 N10: Reduced Therapy for High-Risk Neuroblastoma

Prostate Cancer

NYPC 2020-027  Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer: NCT04842890

Recurrent Cancer

NYPC 2019-002 Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors: NCT05313191

Thoracic Cancers

NRG LU008 Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer: NCT05624996


MSK 22-098 Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Patients With Pleural Metastases From Thymic Malignancies: NCT05354570

Skin Cancers

MSK 22-090 A Phase II, Multicenter, Single-Arm Clinical Trial of Definitive Radiotherapy And CeMiPlimAb-Rwlc ImmunoTherapy for Locally Advanced, Unresectable Cutaneous Squamous Cell Carcinoma: NCT05574101

All Cancer Types

PCG REG001-09 Evaluation Tracking Project: A Prospective Chart Review of Patients Treated with Radiation Therapy: NCT01255748

Approved by the FDA since 1988, proton therapy is firmly established as an advanced and highly effective treatment for cancer that can reduce treatment related toxicities, better preserve quality of life, and improve outcomes for patients.

How can we help?

Want to find out if proton therapy might be a good fit for you or your patient? Call us at 833-NYPROTON (833-697-7686) or fill out the appropriate form below.